Supervised oral protein supplementation during dialysis in patients with elevated C-reactive protein levels: a two phase, longitudinal, single center, open labeled study by Srinivasan Beddhu et al.
RESEARCH ARTICLE Open Access
Supervised oral protein supplementation
during dialysis in patients with elevated
C-reactive protein levels: a two phase,
longitudinal, single center, open labeled study
Srinivasan Beddhu1,2*, Rebecca Filipowicz2, Xiaorui Chen2, Jill L Neilson2, Guo Wei2, Yufeng Huang2 and Tom Greene2
Abstract
Background: Inflammation is considered one of the major causes of protein-energy wasting in maintenance
hemodialysis (MHD) patients. It is unclear whether dietary interventions can impact nutritional status and quality of
life in MHD patients with elevated C-reactive protein (CRP) levels. Therefore, we examined the hypothesis that
supervised intra-dialysis protein supplementation in MHD patients with elevated plasma CRP will improve protein
stores and quality of life.
Methods: A 24 week, two phase, longitudinal, single center, open labeled study of 50 MHD patients with plasma
CRP > 3 mg/L was conducted. During the 12-week observation phase dietary advice was provided to increase
protein intake to 1.2 g/kg/day. In the 12-week treatment phase 45 g of liquid protein supplement was provided at each
dialysis treatment. Protein nitrogen appearance (PNA), mid-arm muscle circumference (MAMC), serum albumin, body
mass index (BMI) and quality of life (assessed by Short Form-12 questionnaire) were measured at baseline, 12 and
24 weeks.
Results: Median plasma CRP at baseline was 16.0 (IQR 7.7 to 25.1) mg/L. The mean MAMC was 26.5 ± 3.9 cm, BMI
29.2 ± 6.9 kg/m2 and plasma albumin 3.8 ± 0.3 g/dl. During the intervention period, mean PNA increased by
0.13 g/kg/d (p = 0.01) under a mixed effects model. However, there were no clinically or statistically significant
effects on MAMC (p = 0.87), plasma albumin (p = 0.70), BMI (p = 0.09), physical (p = 0.32) or mental (p = 0.96)
composite scores.
Conclusions: In MHD patients with elevated plasma CRP but otherwise mostly normal nutritional parameters,
intra-dialytic oral protein supplement was effective in increasing protein intake but did not provide a detectable
impact on nutritional status or quality of life.
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Background
The one and three year survival probabilities of incident
hemodialysis patients are dismal at 74 % and 50 %, respect-
ively [1]. Protein-energy wasting (PEW) is prevalent in
maintenance hemodialysis (MHD) patients, and is by far
one of the strongest risk factor for poor outcomes and death
in this population [2, 3]. Anorexia and hypercatabolism
induced by inflammation is widely considered the under-
lying cause of PEW in MHD patients [4]. However, it is un-
clear whether protein supplementation affects body
composition, body size and quality of life in MHD patients
with elevated C-reactive protein (CRP) levels. Therefore, in
an open labeled interventional trial, we examined the hy-
pothesis that supervised protein supplementation during
dialysis in MHD patients with elevated serum CRP will im-
prove protein stores (as measured by mid-arm muscle cir-
cumference (MAMC) and plasma albumin), body size (as
measured by body mass index (BMI)) and quality of life (as
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measured by Physical and Mental Composite Scores calcu-
lated from Short Form-12 (SF-12) questionnaire).
Methods
This study was conducted between November 13, 2009
and December 18, 2010. The study protocol was ap-
proved by the University of Utah IRB. All the partici-
pants gave written informed consent.
Adult men and women (age ≥ 18 years) who were on
hemodialysis for at least 3 months with serum CRP >
3 mg/L and urea reduction ratio > 65 % who gave in-
formed consent to participate in the study were in-
cluded. Exclusion criteria were patients who were unable
to give informed consent, prisoners or pregnant women,
current active malignancy (excluding squamous and
basal cell carcinoma), active AIDS, and cirrhosis/active
liver disease with poor prognosis.
Study design and procedures
This study was designed as a 24-week, two phase, longi-
tudinal, single center, open labeled study using conveni-
ence sampling. Predialysis blood was obtained for
measurement of plasma high-sensitivity CRP (hsCRP) and
those with levels > 3 mg/L were included in the study.
During the observation phase, all participants received
dietary advice to increase protein intake to 1.2 g/kg/day
and were monitored for 12 weeks. If they were already on
a protein supplement they were advised to continue that
supplementation during the observational phase.
During the treatment phase, in addition to the protein
supplementation if any that the participant was on, super-
vised supplementation on each dialysis session was pro-
vided. Each participant received 45 g of liquid protein
supplement (Provide Sugar Free produced by Provide Nutri-
tion LC) at each dialysis treatment for additional 12 weeks
for total study duration of 24 weeks. Nutrition content in-
formation of the supplement is provided in the Additional
file 1: Appendix Table 4 and Appendix Figure 1 [5].
Clinical and anthropometric measurements
Anthropometric measurements were obtained at base-
line, 12 and 24 weeks following standardized protocols
by trained renal dieticians. Triceps skin fold thickness
was measured with Lange calipers at the back of the
arm at the halfway point between the olecranon process
of the ulna and the acromion process of the scapula with
the person standing upright and arms hanging down
loosely. The skin fold was pulled away from the muscle
and measured with the calipers, taking a reading 4 s after
the calipers have been released. At the same point, mid-arm
circumference was measured with a non-stretchable tape
measure. MAMC in cm was calculated as mid-arm circum-
ference (cm) - (0.314 x triceps skinfold in mm) [6]. Patients’
weight, height, and waist circumferences were obtained
predialysis during midweek sessions (Wednesday for MWF,
Thursday for TuThSat). Post-dialysis weight was also mea-
sured and BMI was calculated as post-dialysis weight divided
by height squared (in kilograms per square meter).
Quality of life was measured at baseline, 12, and
24 weeks using the SF-12, a validated instrument asses-
sing general health employing a Physical Component
Summary (PCS) and the Mental Component Summary
(MCS) [7]. Mid-week pre and post dialysis blood sam-
ples were drawn in lithium heparin tubes at baseline, 12,
and 24 weeks. The blood sample was centrifuged within
15 min and the plasma divided into multiple aliquots of
1 ml each and frozen immediately with dry ice and
transferred to a −80 °C freezer. In those who reported
having a urine output of at least 1 cup/day, 44 h urine
was collected from the end of first dialysis treatment of
the week to the beginning of the mid-week dialysis at
baseline, 12 and 24 weeks. Participants were instructed to
store the urine samples in a cold place and bring it with
them to the dialysis unit. 1.8 ml of urine sample was ali-
quoted in a tube and was transported from the dialysis
unit to the −80 °C freezer on dry ice. hsCRP was measured
using a latex-particle enhanced immunoturbidimetric
assay kit (Roche Diagnostics, Indianapolis, IN 46250) and
read on the Roche Modular P Chemistry analyzer (Roche
Diagnostics) at the University of Utah Associated Regional
University Pathologists (ARUP) Laboratory. Pre and post
dialysis blood urea nitrogen (BUN) and urine urea nitro-
gen were measured using the Roche Modular P Chemistry
analyzer (Roche Diagnostics) at the ARUP Laboratory.
interleukin 6 (IL6) and tumor necrosis factors α (TNFα)
were measured using DuoSet ELISA development system
(Quantikine; R & D Systems Inc.; Minneapolis, MN, USA).
Assessment of adherence
The amount of supplement consumed during each treat-
ment was recorded by the dialysis unit personnel.
Achieved protein supplement dose was calculated from
the amount of protein supplement consumed. In
addition, protein nitrogen appearance (PNA) calculated
[8] from mid-week pre and post-dialysis BUN levels
using a two-BUN measurement, single-pool, variable
volume model as PNA = C0/(25.8 + (1.15/Kt/V) + (56.4/
Kt/V)) + 0.168 where, C0 is predialysis BUN and Kt/V is
dialysis clearance. Kt/V was calculated as Kt/V = -Ln
(R-0.008xt) +4-(3.5x R)) x UF/W where R is the postdialy-
sis/ predialysis BUN ratio, t is the dialysis session in hours,
UF is the ultrafiltration volume in liters, and W is the
postdialysis weight in kilograms [8]. In those with residual
renal function, C0 was upwardly adjusted using the for-
mula Co’ = Co [1 + (0.79+ (3.08)/(Kt/V)) Kr/V], where Kr
is residual urinary urea clearance in mL/min, C0’ and C0
are in mg/dL, and V is in L [8].
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Statistical analysis
Baseline clinical characteristics, protein supplementation
and plasma inflammatory markers levels at baseline and
follow-up were summarized using means and standard de-
viations or by medians and 25th and 75th percentiles for
continuous variables and by proportions for categorical
variables. The effects of the treatment on outcomes were
evaluated primarily by the mean changes in the outcome
variables during the 12-week interventional phase. Sec-
ondary analyses evaluated the difference between the
mean changes of the outcomes during the 12-week inter-
ventional phase and the mean changes during the 12-
week observational phase. The latter assessment evaluates
the change in the mean slope of the outcomes between
the interventional and observational changes, and is
intended to correct for long-term trends in the outcomes
which are independent of the intervention. The mean
changes in both the observational and interventional
phases were estimated by applying mixed effects analyses
using an unstructured covariance model to account for
correlations in measurements across time. These models
were used to characterize mean changes in PNA, MAMC,
plasma albumin, BMI, PCS and MCS. Sensitivity analyses
were performed limiting the mixed effects analyses to only
those with low baseline PNA (<1 g/kg/d) or low plasma al-
bumin (<4 g/dl) or high plasma hsCRP (>10 mg/L).
Additional analyses were conducted in the entire study
population to estimate the mean changes in the outcome
variables during the intervention period after adjusting for
contemporaneous changes during the intervention period
in the pre-dialysis levels of plasma markers of inflamma-
tion (hsCRP, TNFα and IL6), plasma bicarbonate and re-
sidual renal function. These analyses were carried out by
modifying the mixed effects models to relate the mean
changes in the outcomes to the changes in each of the in-
dicated covariates during the interventional phase, and
reporting the estimated mean change in the outcome
when the mean change in each covariate was set to 0.
Analyses of each outcome were performed on a
comparison-wise basis, without adjustment for multiple
comparisons. We performed analyses using STATA 12
and SAS version 9.2.
Furthermore, in order to descriptively compare the
baseline nutritional parameters of this dialysis cohort to
the population norms of adults > 50 years of age, we
used data from 1999 to 2002 National Health And Nu-
trition Examination Survey, the details of which are pub-
lished elsewhere [9]. We used the svy suite in STATA 12
to conduct the National Health and Nutrition Examin-
ation Survey (NHANES) analyses.
Results
The flow of study participants is summarized in Fig. 1.
Seventy-one patients underwent screening visit and of
these, 54 had serum hsCRP > 3 mg/L and were included.
Of these, 50 participants completed baseline visit and
Fig. 1 Flow of study participants
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started the observational phase. Four participants dropped
out during the observational phase. Forty-six participants
started the interventional phase and 5 dropped out during
that phase. Forty-one participants were able to complete
both phases of the study successfully.
Table 1 summarizes the baseline characteristics of the
study dialysis population and a national sample of older
healthy community dwelling adults. As is expected, the
dialysis population had a greater prevalence of comorbidi-
ties. In comparison to the healthy older cohort, the dialysis
population also had very high hsCRP levels, lower plasma
albumin levels and lower muscle mass. Nonetheless, the
dialysis population had higher fat energy stores (as evi-
denced by higher BMI and waist circumference).
Weekly supervised protein supplementation during the
intervention period is summarized in Table 2. At baseline,
12 and 24 weeks, 46 %, 48 % and 46 % of the participants
reported taking an unsupervised protein supplementation
on their own, respectively. The reported mean unsuper-
vised protein supplement intake levels were 63.8 ± 91.8,
62.2 ± 84.9 and 64.9 ± 96.8 g/week, respectively.
Table 3 summarizes the measured PNA from urea kin-
etic modeling, nutritional and quality of life measures,
plasma inflammatory markers and bicarbonate levels
and residual renal function at baseline, week 12 and
week 24. During the observation period mean PNA de-
creased whereas it increased in the intervention period
(Fig. 2). Spearman correlation between the achieved pro-
tein supplement between weeks 12 and 24 and the delta
of PNA between weeks 12 and 24 was 0.45 (p = 0.004).
In the mixed effects analysis, mean PNA significantly in-
creased by 0.13 (95 % CI, 0.03 to 0.22) g/kg/d during the
interventional phase (Table 4, first row). Because PNA de-
clined slightly during the observation period, the change
in PNA during the intervention period was 0.21 (95 % CI,
0.08 to 0.33) g/kg/d greater (p = 0.001) than during the
during the observation period (Table 4). Similar results
were obtained after adjusting for changes during the inter-
vention phase in the levels of markers of inflammation,
plasma bicarbonate and residual renal function (Table 5).
The estimated mean changes of MAMC, plasma albu-
min, BMI and SF-12 during the observational and inter-
ventional phases of the study are provided in Table 4
and in Figs. 3, 4, 5, 6 and 7. Without covariate adjust-
ment, there were no statistically significant mean
changes of any of the outcomes during the intervention
phase (left columns of Tables 4 and Figs. 3, 4, 5, 6 and 7)
and also no statistically significant differences in the
changes between the intervention and observational
phases (right columns of Table 4). It is noteworthy that
the effect sizes for all of the outcome variables were
Table 1 Clinical and nutritional characteristics. Characteristics of
the study dialysis population (n = 50) and adults > 50 years of
age in the US general population (1999–2002 National Health
And Nutrition Examination Survey)
Current study
population (n = 50)
NHANES 99–02 with age
≥ 50 years (n = 4983)a
Demographics
Age (year) 63.8 ± 17.5 64.0 ± 9.2
Women (%) 44.9 54.5











Diabetes (%) 66.7 14.6
Malignancy (%) 14.3 15.7
Smoking (%) 40.8 54.2
Nutritional and inflammatory markers
Body mass index (kg/m2) 29.2 ± 6.9 28.5 ± 5.2
Waist circumference (cm) 106.6 ± 16.7 99.5 ± 12.7
MAMC (cm) 26.5 ± 3.9 32.8 ± 4.1
Plasma albumin (g/dL) 3.8 ± 0.3 4.3 ± 0.3
Plasma hsCRP (mg/L) 16.0 (7.7, 25.1) 0.2 (0.1, 0.5)
Dialysis and Renal
Characteristics
Duration of ESRD (years) 3.0 (1.4, 4.8) NA
AV Fistula (%) 77.6 NA
Kt/V 1.6 ± 0.2 NA
Proportion with urine
output > 1 cup/day (%)
34.7 NA
aAdjusted for NHANES survey weight
Table 2 Weekly average of supervised protein supplementation
during dialysis in the interventional period
Week N N non-adherenta g/week g/kg/d
13 46 2 (4.3 %) 118.0 ± 32.2 0.21 ± 0.07
14 45 3 (6.7 %) 117.0 ± 37.6 0.21 ± 0.07
15 45 7 (15.6 %) 106.3 ± 47.4 0.18 ± 0.09
16 45 7 (15.6 %) 101.7 ± 51.6 0.18 ± 0.10
17 45 7 (15.6 %) 95.0 ± 51.7 0.16 ± 0.09
18 44 8 (18.2 %) 94.8 ± 51.9 0.16 ± 0.10
19 44 6 (13.6 %) 108.1 ± 46.4 0.19 ± 0.09
20 44 6 (13.6 %) 107.4 ± 48.7 0.18 ± 0.09
21 42 6 (14.3 %) 103.9 ± 50.2 0.18 ± 0.09
22 42 7 (16.7 %) 105.0 ± 52.3 0.18 ± 0.10
23 42 8 (19.0 %) 97.5 ± 53.4 0.17 ± 0.10
24 41 8 (19.5 %) 86.0 ± 57.1 0.15 ± 0.10
aNon-adherence to intervention was defined as consumption of < 50 % of provided
protein supplement or continuing in the study after stopping the intervention
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small with relatively narrow confidence intervals sug-
gesting that type 2 error (falsely negative results due to
failure to detect clinically important effects of protein
supplementation on these parameters) is unlikely.
When further adjusted for plasma markers of inflam-
mation and bicarbonate and residual renal function, the
results were similar (Table 5).
The results were also similar in subgroups defined by
baseline PNA or plasma albumin or plasma hsCRP
(please see Additional file 1: Appendix Tables 1-3).
Discussion
Seventy-six percent of the screened dialysis patients in
this study had plasma hsCRP levels > 3 mg/L indicating
that inflammation is highly prevalent in dialysis patients.
Compared to the healthy community dwelling older
adults, these dialysis patients appear to have lower pro-
tein stores (as evidenced by lower serum albumin and
lower muscle mass) but higher energy stores (as evi-
denced by higher BMI and higher waist circumference).
Furthermore, in dialysis patients with inflammation,
intra-dialytic oral protein supplementation was effective
in producing a clinically meaningful increase in protein
intake as measured by PNA. However, protein supple-
mentation did not impact on muscle mass, plasma albu-
min or quality of life in these hemodialysis patients. The
following discussion interprets these findings in the con-
text of existing literature.
The current national guidelines recommend a dietary
protein intake of 0.8 g/kg/d in the general population
and 1.2 g/kg/d in hemodialysis patients [10]. These rec-
ommendations are largely based upon observational data
that suggest that low protein intake as well as markers
of PEW is associated with increased mortality. There has
been only one randomized controlled trial that examined
the effects of protein supplementation on mortality in
dialysis patients. However, that study compared intra-
Table 3 Measured protein nitrogen appearance, nutritional and
quality of life measures, plasma inflammatory markers and








PNA (g/kg/day) 1.12 ± 0.32 1.04 ± 0.30 1.18 ± 0.35
MAMC (cm) 26.5 ± 3.9 26.2 ± 4.0 26.6 ± 4.3
Plasma albumin (g/dL) 3.76 ± 0.31 3.79 ± 0.33 3.75 ± 0.35
Body Mass Index
(kg/m2)
29.2 ± 6.9 29.0 ± 6.9 28.8 ± 5.6
SF12 - Physical Health
Composite Scale
Scores
29.3 ± 9.6 30.6 ± 9.9 29.2 ± 9.0
SF12 - Mental Health
Composite Scale
Scores
51.4 ± 11.3 50.9 ± 11.1 50.6 ± 13.1
Plasma hsCRP (mg/L) 16.0 (7.7, 25.1) 10.9 (6.4, 25.3) 14.0 (7.9, 38.0)
Plasma TNF-α (pg/ml) 15.4 (9.1, 43.0) 17.4 (11.0, 41.8) 19.3 (12.4, 94.4)
Plasma IL6 (pg/ml) 10.7 (5.1, 20.2) 13.2 (8.9, 19.9) 12.8 (5.0, 35.5)
Plasma bicarbonate
(mmol/L)
24.2 ± 4.4 26.1 ± 3.1 26.3 ± 3.4
% with residual renal
function
34.7 26.1 20.5
24-h urine volume in
those with residual
renal function (ml/d)
648.0 ± 374.3 562.5 ± 371.6 643.9 ± 331.3
aMean ± SD or median (25th, 75th percentiles) presented
Fig. 2 Changes in protein nitrogen appearance during the observational
and interventional phases
Table 4 Mixed effects models of changes in protein intake and
outcome variables
Δ interventional phase
(95 % CI), p values
Δ interventional
phase – Δ observational
phase (95 % CI), p values
PNA (g/kg/day) 0.13 (0.03, 0.22), p = 0.01 0.21 (0.08, 0.33), p = 0.001
MAMC (cm) 0.06 (−0.62, 0.73), p = 0.87 0.02 (−1.16, 1.21), p = 0.97
Plasma albumin
(g/dL)
−0.01 (−0.09, 0.06), p = 0.70 −0.05 (−0.16, 0.06), p = 0.35
BMI (kg/m2) −0.22 (−0.47, 0.03), p = 0.09 −0.24 (−0.66, 0.18), p = 0.25
SF12- PCS −1.39 (−4.15, 1.38), p = 0.32 −2.55 (−6.49, 1.38), p = 0.20
SF12- MCS 0.07 (−2.70, 2.85), p = 0.96 0.74 (−4.46, 5.94), p = 0.78
Table 5 Additional analysis by mixed effects modelsa of changes
in outcome variables adjusted for plasma levels of markers of
inflammation and bicarbonate and residual renal function
Δ interventional phasea (95 % CI), p values
PNA (g/kg/day) 0.17 (0.05, 0.29),p = 0.005
MAMC (cm) 0.50 (−0.39, 1.40),p = 0.262
Plasma albumin (g/dL) −0.04 (−0.14, 0.05),p = 0.368
BMI (kg/m2) −0.19 (−0.53, 0.16),p = 0.282
SF12- PCS −2.91 (−6.86, 1.04),p = 0.145
SF12- MCS 1.18 (−1.77, 4.12),p = 0.426
aAdjusted for the change in interventional phase in plasma hsCRP, TNFα, IL6
and bicarbonate and residual renal function
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dialytic parenteral nutrition (IDPN) vs. oral protein sup-
plement and did not include an usual care arm [11]. In
that study, in both groups PNA increased along with an
increase in body weight and serum albumin but there
were no differences between the two groups regarding
the primary endpoint of mortality [11].
Muscle is the largest protein store in the body. Short
term amino-acid labeling studies suggest that protein sup-
plementation could improve muscle anabolism [12]. How-
ever, there is surprisingly very little data on the effects of
protein supplementation on muscle mass in hemodialysis
patients. In an earlier smaller study of 20 dialysis patients,
protein supplementation did not impact on muscle mass
[13]. In the current study also we did not observe an effect
of protein supplementation on MAMC.
Non-randomized and randomized trials that examined
the impact of protein supplementation on serum albu-
min in dialysis patients have yielded mixed results. Some
of the trials showed clinically meaningful increases in
serum albumin levels [14–16], whereas others showed
very modest increases [11, 13, 17–20] or no detectable
effects [21]. Two recent large observational studies of
oral nutritional supplement suggested a better survival
with nutritional supplement [22, 23] however, in one of
those studies [22] follow-up serum albumin levels were
not available and in the other study [23], no effects of nu-
tritional supplementation on serum albumin was ob-
served. In the current study, we did not note a significant
change in plasma albumin with protein supplementation.
The dose of supervised dialysis protein supplementa-
tion in this study (45 g/dialysis session) was much higher
than the doses of 16.6 g per dialysis session [16] and
31.5 g per dialysis session [20] in earlier studies. The
lack of detectable effects on muscle mass and serum al-
bumin despite a clinically meaningful increase in PNA
might be ascribed to the high CRP (median 16.0, IQR
7.7 to 25.1 mg/L) levels in this cohort. However, in the
study by Cano et al., there was modest increase in serum
albumin in those treated with oral/ parenteral protein
supplementation in the presence or absence of elevated
CRP [11]. Hence, it is unlikely that inflammation is the
reason for the negative results in the current study.
Fig. 3 Changes in mid-arm muscle circumference during the
observational and interventional phases
Fig. 4 Changes in plasma albumin during the observational and
interventional phases
Fig. 5 Changes in body mass index during the observational and
interventional phases
Fig. 6 Changes in physical health composite scale scores during the
observational and interventional phases
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It should be noted that the upper bounds of the 95 %
confidence interval for treatment effects of MAMC were
0.73 cm, plasma albumin 0.06 g/dl and BMI 0.03 kg/m2
(Table 4). The small magnitudes of these upper endpoints
suggest that while the possibility of positive treatment ef-
fects cannot be ruled out by this study (i.e., the null hy-
pothesis cannot be shown to be true), any such
undetected effects are likely to have been relatively small.
Compared to the national norms (Table 1), despite the
higher prevalence of comorbidity, higher concentrations
of hsCRP, lower concentrations of plasma albumin and
lower muscle mass, dialysis patients do not appear to be
“wasted” in the sense that they have higher BMI and
higher waist circumference. Hence, they do not appear
to have lower energy stores. Therefore, the reason for
lack of a beneficial effect of protein supplementation in
this study on nutritional markers might be because these
patients might not need protein supplementation in the
first place. Indeed in studies where the BMI was low [11,
15] or serum albumin was low [11, 14, 15], protein supple-
mentation was effective in increasing serum albumin and
body weight. Furthermore, in a non-randomized observa-
tional study of dialysis patients with serum albumin ≤ 3.5 g/
dL, those who received nutritional supplement had better
survival compared to those who did not [22]. In other
words, despite the current recommendations to increase
PNA in all dialysis patients to 1.2 g/kg/d, nutritional inter-
ventions might need to be more carefully targeted to those
with poor nutrition as evidenced by low BMI or low
serum albumin.
Nonetheless, the current guidelines and clinical practice
are to target with protein supplementation a PNA of
1.2 g/kg/d and serum albumin of 4 g/dl. Hence, the
current study was designed to examine the effects of oral
protein supplementation on nutritional markers in in-
flamed dialysis patients. To our knowledge, this is the first
study to examine the impact of protein supplementation
on nutritional markers in hemodialysis patients with ele-
vated plasma CRP levels.
The limitations of the study include a lack of parallel
arm randomized controlled design, shorter duration and
smaller number of participants. Nonetheless, these limi-
tations also apply to most of the above mentioned inter-
ventional studies on protein supplementation in dialysis
patients. Protein sources rich in branched chain amino
acids might be beneficial [24] but this study was not de-
signed to examine that hypothesis. While protein intake
was objectively measured with urea kinetic modeling, en-
ergy intake was not measured in this study. Finally, BMI,
which is based on the height and weight of an individual,
is an inaccurate indicator of body composition because it
does not take into account muscle mass. We used MAMC
as the main measure of muscle mass in this study and we
did not obtain other measures such as computed tomog-
raphy (CT) or magnetic resonance imaging (MRI) scans
or dual energy x-ray absorptiometery (DEXA).
Conclusion
In summary, most dialysis patients have inflammation as
defined by elevated CRP levels. Despite, the high CRP
levels and lower plasma albumin and MAMC, dialysis pa-
tients appear to have higher energy stores. High dose
intra-dialytic protein supplementation did not affect
MAMC, body weight or plasma albumin in this relatively
well-nourished dialysis patients. Interventional studies tar-
geting those with evident malnutrition as defined by lower
body size or low muscle mass are needed to define the
role of dietary interventions in dialysis patients.
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